Retatrutide (development code LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Taken together, these patterns suggest that GLP-1 adoption is not only transforming diabetes and obesity care but also influencing prescribing behavior and patient management across a broader set of comorbid markets
Lisa proudly serves patients throughout Lake Mary, Winter Park, Heathrow, Longwood, Maitland, Altamonte Springs, Seminole County, Orange County, and surrounding Central Florida communities, helping people feel more like themselves again through care that is both clinically rigorous and genuinely personal
Is Semaglutide GLP-1 effective for medical weight loss
KristiansenSBHenningOKharbandaRKNielsen-KudskJESchmidtMRRedingtonANet al